Entera Bio’s Promising Phase 3 Study and Market Potential Drive Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Entera Bio, with a price target of $10.00.

Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Entera Bio’s promising developments. One significant reason is the FDA’s agreement to use bone mineral density (BMD) as the primary endpoint for Entera Bio’s pivotal Phase 3 study of EB613, a treatment for post-menopausal osteoporosis. This agreement allows the company to progress its clinical program without waiting for further regulatory qualifications, potentially accelerating partnership or licensing opportunities.
Furthermore, the global need for innovative osteoporosis treatments is substantial, with over 200 million women affected by the condition and a lack of new drug approvals since 2019. Entera Bio’s EB613, being developed as the first oral anabolic tablet for osteoporosis, has shown promising clinical data, including rapid increases in bone formation markers and BMD. These factors, along with the anticipation of a key regulatory ruling that could further mitigate risks, underpin Selvaraju’s positive outlook and Buy rating for Entera Bio.